GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Proteome Therapeutics Corp (OTCPK:APTCF) » Definitions » Long-Term Debt & Capital Lease Obligation

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Long-Term Debt & Capital Lease Obligation : $0.00 Mil (As of Apr. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Advanced Proteome Therapeutics Long-Term Debt & Capital Lease Obligation?

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Advanced Proteome Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2023 was $0.00 Mil.

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligation divides by its Total Assets. Advanced Proteome Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Apr. 2023 was $0.00 Mil. Advanced Proteome Therapeutics's Total Assets for the quarter that ended in Apr. 2023 was $0.06 Mil. Advanced Proteome Therapeutics's LT-Debt-to-Total-Asset for the quarter that ended in Apr. 2023 was 0.00.

Advanced Proteome Therapeutics's LT-Debt-to-Total-Asset declined from Apr. 2022 (0.21) to Apr. 2023 (0.00). It may suggest that Advanced Proteome Therapeutics is progressively becoming less dependent on debt to grow their business.


Advanced Proteome Therapeutics Long-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Advanced Proteome Therapeutics's Long-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Proteome Therapeutics Long-Term Debt & Capital Lease Obligation Chart

Advanced Proteome Therapeutics Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Long-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.14 0.15 0.17 0.23

Advanced Proteome Therapeutics Quarterly Data
Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23
Long-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.23 0.22 0.24 -

Advanced Proteome Therapeutics Long-Term Debt & Capital Lease Obligation Calculation

Long-Term Debt is the debt due more than 12 months in the future. The debt can be owed to banks or bondholders. Some companies issue bonds to investors and pay interest on the bonds.

Long-Term Capital Lease Obligation represents the total liability for long-term leases lasting over one year. It's amount equal to the present value (the principal) at the beginning of the lease term less lease payments during the lease term.

The interest paid on companies' debt is reflected in the income statement as interest expense. If a company has too much debt and it cannot serve the interest payment on the debt or repay the matured debt, the company risks bankruptcy. Peter Lynch famously said: A company that does not have debt cannot go bankrupt.

A company's long term debt may have different dates of maturity and interest rates, depending on the terms.

Usually a company issues long term debt to pay for its capital expenditures. Borrowing allows the company to do things that otherwise cannot be done with only the capital it has. But debt can be risky.


Advanced Proteome Therapeutics  (OTCPK:APTCF) Long-Term Debt & Capital Lease Obligation Explanation

LT-Debt-to-Total-Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Advanced Proteome Therapeutics's LT-Debt-to-Total-Asset ratio for the quarter that ended in Apr. 2023 is calculated as:

LT-Debt-to-Total-Asset (Q: Apr. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Apr. 2023 )/Total Assets (Q: Apr. 2023 )
=0/0.063
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Buffett says that durable competitive advantages carry little to no long-term debt because the company is so profitable that even expansions or acquisitions are self financed.

We are interested in long term debt load for the last ten years. If the ten years of operation show little to no long term debt, then the company has some kind of strong competitive advantage.

Warren Buffett's historic purchases indicate that on any given year, the company should have sufficient yearly net earnings to pay all long term within 3 or 4 year earnings period. (e.g. Coke + Moody's = 1yr)

Companies with enough earning power to pay long term debt in less than 3 or 4 years is a good candidate in our search for long term competitive advantage.

BUT, these companies are targets for leveraged buy outs, which saddles the business with long term debt.

If all else indicates the company has a moat, but it has ton of debt, a leveraged buyout may have created the debt. In these cases the company's bonds offer the better bet, in that the company’s earnings power is focused on paying off the debt and not growth.

Important: little or no long term debt often means a Good Long Term Bet


Advanced Proteome Therapeutics Long-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Advanced Proteome Therapeutics's Long-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Business Description

Traded in Other Exchanges
Address
8337 Eastlake Drive, Suite 104, Burnaby, BC, CAN, V5A 4W2
Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.

Advanced Proteome Therapeutics (Advanced Proteome Therapeutics) Headlines